Cumberland Pharmaceuticals (CPIX) Net Income towards Common Stockholders (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Net Income towards Common Stockholders of -$3.1 million for Q1 2026, down 121.91% sequentially from -$1.4 million in Q4 2025, and down 351.64% YoY from $1.2 million in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$3.1 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 351.64% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 119.88% YoY) and the FY2025 annual result came in at -$2.9 million, up 55.75% from the prior year.
- Net Income towards Common Stockholders eased to -$3.1 million in Q1 2026 per CPIX's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $1.2 million in Q1 2025 and troughed at -$6.3 million in Q4 2023.
- A 4-year average of -$1.4 million and a median of -$1.4 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 1204.25% in 2024, then surged 165.61% in 2025.
- Over 4 years, Net Income towards Common Stockholders stood at -$6.3 million in 2023, then soared by 69.82% to -$1.9 million in 2024, then climbed by 25.57% to -$1.4 million in 2025, then plunged by 121.91% to -$3.1 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$3.1 million, -$1.4 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 117.61 Mn | 113.74 Mn | - | -4.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.17 Mn |
| Mar 31, 2026 | -3.14 Mn |
| Dec 31, 2025 | -1.42 Mn |
| Sep 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -735,207.00 |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -6.30 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | 862,154.00 |
| Mar 31, 2023 | 172,286.00 |
| Dec 31, 2021 | 503,318.00 |
| Sep 30, 2021 | 496,787.00 |
| Jun 30, 2021 | 498,807.00 |
| Mar 31, 2021 | 495,410.00 |
| Dec 31, 2020 | 872,064.00 |
| Sep 30, 2020 | 777,916.00 |